Bank of New York Mellon’s Apogee Therapeutics APGE Stock Holding History
Bought
Maintained
Sold
Other funds holding APGE
RCP
AIMCA
CCM
Bank of New York Mellon's APGE Position: Q2 2026 in Review
Bank of New York Mellon increased its Apogee Therapeutics (APGE) stake by 21% in Q2 2026, buying an estimated $2.35M and bringing the position to 152,815 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1614.
Bank of New York Mellon first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 86 funds tracked by Wall St. Rank hold APGE as of Q2 2026.
- Bank of New York Mellon held 152,815 shares of Apogee Therapeutics worth $20.3M as of Q2 2026.
- Bank of New York Mellon bought 26,058 Apogee Therapeutics shares in Q2 2026, an estimated $2.35M.
- Apogee Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1614 holding.
- Bank of New York Mellon first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
- 86 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.